Impel Pharmaceuticals Announces Exploration of Strategic Alternatives
October 05, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative...
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
May 10, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering...
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 24, 2023 08:17 ET
|
Impel Pharmaceuticals
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to...
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
March 17, 2023 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
March 03, 2023 16:01 ET
|
Impel Pharmaceuticals
SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
February 22, 2023 16:30 ET
|
Impel Pharmaceuticals
Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 PercentCompany will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial...
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 08:00 ET
|
Impel Pharmaceuticals
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million Trudhesa surpasses 5% of Acute Branded Prescriptions among prescribers in Q3 One Year...
Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day
November 08, 2022 16:21 ET
|
Impel Pharmaceuticals
SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 07, 2022 16:01 ET
|
Impel Pharmaceuticals
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 08:05 ET
|
Impel Pharmaceuticals
Trudhesa® TRx’s Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market...